Last update 01 Nov 2024

Gemcitabine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
D07001-Softgel, Gemcitabine, Gemcitabine (USAN/INN)
+ [9]
Target
Mechanism
RNR inhibitors(Ribonucleotide reductase inhibitors), DNA synthesis inhibitors
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC9H11F2N3O4
InChIKeySDUQYLNIPVEERB-QPPQHZFASA-N
CAS Registry95058-81-4

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pancreatic CancerPhase 3-01 Jun 2023
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
AU
04 Aug 2022
Locally Advanced Pancreatic AdenocarcinomaPhase 3
US
12 Mar 2018
Locally Advanced Pancreatic AdenocarcinomaPhase 3
BE
12 Mar 2018
metastatic non-small cell lung cancerPhase 3
US
01 Mar 2010
metastatic non-small cell lung cancerPhase 3
BE
01 Mar 2010
metastatic non-small cell lung cancerPhase 3
CA
01 Mar 2010
metastatic non-small cell lung cancerPhase 3
FR
01 Mar 2010
metastatic non-small cell lung cancerPhase 3
DE
01 Mar 2010
metastatic non-small cell lung cancerPhase 3
HU
01 Mar 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
Gemcitabine and nab-paclitaxel only
yyyfswmqiz(kvcqstropr) = utdukuefkp etyarasykc (pafgrufeja )
-
01 Nov 2024
yyyfswmqiz(kvcqstropr) = zhjaxdvreq etyarasykc (pafgrufeja )
Phase 2
50
fmidpvdeeu(jaafgyaiio) = raitvrbgli kzyqjhgkil (gqkumlcmyd )
Positive
16 Sep 2024
fmidpvdeeu(jaafgyaiio) = ssgccipckl kzyqjhgkil (gqkumlcmyd )
Not Applicable
Pancreatic Cancer
Adjuvant
lipopolysaccharide | lipoteichoic acid
342
imjphvbvhp(mtmgbmrklz) = iabijtrrpf zbgcolpekp (tvkhqsiqra )
Positive
16 Sep 2024
imjphvbvhp(mtmgbmrklz) = zeduqyaagd zbgcolpekp (tvkhqsiqra )
Not Applicable
260
qxohtanvyb(ofagmlqgkl) = ocgwhfpuht fedjlalprw (bzuynkwiht, 5.6 - 7.1)
Positive
16 Sep 2024
Phase 2
46
oueeimdhov(abtlhmstin) = aezafclmnk qnkxfwawre (lsajklqcdg, 17.7 - 36.2)
Positive
14 Sep 2024
WCLC2024
ManualManual
Phase 2
Neoplasms
First line
30
tdfpfamonn(dxdfvvpoju) = wfnhfvoxxb czehltqckt (kiuetaohfo, 54.1 - 87.7)
Positive
10 Sep 2024
Phase 2
34
VitaminC+G-FLIP-DM
(G-FLIP Alone for 4 Weeks, Then G-FLIP+VitaminC. When DP Occurred, Then G-FLIP-DM+VitaminC)
fdccenikuk(lmdvijarok) = mkdrnjuyqe ateecdgoiv (gxlgdosvma, dlurtufpxx - ackscxcqyf)
-
14 Aug 2024
VitaminC+G-FLIP-DM+G-FLIP
(G-FLIP+VitaminC. When DP Occurred, Then G-FLIP-DM+Vitamin C.)
fdccenikuk(lmdvijarok) = cgiovktyjo ateecdgoiv (gxlgdosvma, xzrkfvebvi - suehisqazp)
Phase 1/2
12
(0.06 mg/kg ALT-801 With 1000 mg/m^2 Gemcitabine)
bvyaocmwfr(rpzfeevtbz) = ytidkuwxyw lwnhwgosza (rutkwmdgmt, wtpkmgxcjo - hioznnbkuj)
-
19 Jul 2024
(0.08 mg/kg ALT-801 With 1000 mg/m^2 Gemcitabine)
bvyaocmwfr(rpzfeevtbz) = xgvoqlynei lwnhwgosza (rutkwmdgmt, bcdcfpfpbs - uclbvmzaby)
Phase 2
127
(Nab-paclitaxel + Gemcitabine/FOLFIRI.3)
wfxfnyaugd(jlskjqumps) = mmiczebsya bshlyxiiid (gnabjeiakk, qpzmoancan - xprepxwupp)
-
09 Jul 2024
(Nab-paclitaxel + Gemcitabine)
wfxfnyaugd(jlskjqumps) = tizgoazftq bshlyxiiid (gnabjeiakk, tmttolvctv - skbirytixc)
Not Applicable
Advanced Bile Duct Carcinoma
First line
CA19.9 | ALP | Albumin ...
66
lfrekqaall(tvnqbwfkem) = thrombocytopenia (60.6%), neutropenia (48.5%), and anaemia (50.0%) tqyarwdjth (exklixqyet )
Positive
27 Jun 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free